Listata mini, 60 mg 80 pcs

Listat mini is a lipase inhibitor.

Ingestion of orlistat inhibits gastric and pancreatic lipases. As a result, the breakdown of dietary fats is impaired and their absorption from the gastrointestinal tract is reduced.

When used systemically this effect leads to weight loss in obese patients.

Orlistat is practically not absorbed from the gastrointestinal tract and therefore has almost no resorptive effect.

Indications

Long-term therapy of obese patients with a BMI of 30 kg/m2 or overweight patients with a BMI of 28 kg/m2 or greater, including those with risk factors associated with obesity. with obesity-associated risk factors, in combination with a moderately hypocaloric diet.

Active ingredient

Composition

Active ingredient:

orlistat 60 mg;

Excipients:

sodium lauryl sulfate – 12 mg;

acacia gum – 210 mg;

ludiflash (mannitol – 84-92%, crosspovidone – 4-6%, polyvinyl acetate – 3.5-6%, povidone – 0.25-0.6%) – 640 mg;

copovidone – 20 mg;

crospovidone – 50 mg;

magnesium stearate – 8 mg;

film jacket:

Opadray II blue (85F30720) (polyvinyl alcohol – 40%, titanium dioxide – 21.4%, macrogol 3350 – 20.2%, talc – 14.8%, quinoline yellow aluminum varnish – 0.1%, indigo carmine – 3.5%) – 34.8 mg; Opadray silver (63F97546) (polyvinyl alcohol – 47.03%, talc – 27%, macrogol 3350 – 13.27%, pearlescent pigment – 10%, polysorbate 80 – 2.7%) – 6 mg.

How to take, the dosage

Ingestion with water immediately before a meal, with a meal, or no later than 1 hour after a meal.

The recommended dose is 60 mg 3 times daily with each main meal, combined with a moderately hypocaloric, low-fat diet. If a meal is skipped or the food is fat-free, the Lystata Mini should be skipped.

The maximum daily dose is 3 tablets of 60 mg.

The treatment is recommended for no more than 6 months. If after 12 weeks of therapy there is no decrease in body weight (ie, weight loss is less than 5% of baseline), it is necessary to consult a physician to decide whether to continue the use of the drug.

Patient special groups

Elderly patients, patients with hepatic and renal dysfunction. No dose adjustment is necessary.

Children. Listata Mini is not recommended for use in children and adolescents less than 18 years of age because of insufficient data on safety and efficacy.

Interaction

Concomitant administration of orlistat and cyclosporine may decrease the plasma concentration of cyclosporine, therefore it is necessary to monitor the plasma concentration of cyclosporine. Simultaneous use of Listat Mini and cyclosporine is contraindicated.

Concomitant use of Orlistat with amiodarone may decrease the plasma concentration of amiodarone. The clinical significance of this effect is unclear. Concomitant use of orlistat and warfarin or other oral anticoagulants may decrease prothrombin concentration and increase INR.

The concomitant use of Listat Mini and warfarin or other oral anticoagulants is contraindicated.

Orlistat may decrease absorption of fat-soluble vitamins A, D, E, K and beta-carotene. If multivitamins are indicated, they should not be taken before 2 hours after taking Orlistat or before bedtime.

Orlistat can decrease absorption of antiepileptic drugs, which can lead to seizures.

Because of the lack of pharmacokinetic interaction studies, co-administration of orlistat and acarbose is not recommended.

In some cases orlistat may indirectly decrease the bioavailability of oral contraceptives. An additional contraceptive method is recommended in cases of severe diarrhea.

In concomitant administration with levothyroxine sodium, due to decreased absorption of inorganic iodine and/or levothyroxine sodium, hypothyroidism and/or decreased control of hypothyroidism may develop.

Special Instructions

Diet and exercise are important components of a weight loss program. It is recommended to start a dietary program and exercise before starting therapy with Listat Mini. The patient should receive a moderately hypocaloric diet containing no more than 30% of calories in the form of fat (e.g. at a caloric value of 2000 kcal/day, a meal should contain no more than 67 g of fat).

The daily fat intake should be divided among the three main meals.

Low-fat diets decrease the likelihood of GI adverse events.

Patients taking antiepileptic drugs should consult their physician before starting Lystata Mini, as the frequency and severity of seizures may change. In these cases, you may consider taking Orlistat and antiepileptic drugs at different times.

Patients with renal disease should consult a physician, as hyperoxaluria and nephropathy may develop.

With the reduction of body weight through taking Listat Mini, carbohydrate metabolism in patients with type 2 diabetes may improve, so the physician should be consulted before starting Orlistat and the dose of hypoglycemic drugs decreased, if necessary. Patients taking hypotensive and hypolipidemic medications should consult a physician before starting orlistat and adjust the dose of these medications, if necessary.

In case of symptoms such as weakness, fatigue, fever, jaundice, and darkened urine, a physician should be consulted to rule out liver function abnormality.

Orlistat does not affect the ability to drive vehicles and operate mechanisms.

Contraindications

Hypersensitivity to orlistat or any other ingredients of the drug;

Chronic malabsorption syndrome;

pregnancy;

breastfeeding period;

Side effects

Gastrointestinal disorders: very common – oily discharge from the rectum, discharge of gas with some discharge, imperative defecation urges, steatorrhea; common – abdominal pain, fecal incontinence, liquid stools, increased frequency of defecation.

Some side effects reported in the post-marketing period (frequency unknown)

Gastrointestinal disorders: minor bleeding from the rectum, diverticulitis.

Hepatic and biliary tract disorders: increased hepatic transaminases and TSH activity, hepatitis, cholelithiasis.

Skin and subcutaneous tissue disorders: bullous rash.

Immune system disorders: hypersensitivity reactions (itching, rash, urticaria, angioedema, bronchospasm and anaphylaxis).

Others: decreased prothrombin concentration, increased INR in patients who have taken orlistat together with indirect anticoagulants.

Similarities